There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Spark Therapeutics (NASDAQ: ONCE) and uniQure NV (NASDAQ: QURE) with bullish sentiments.
Spark Therapeutics (NASDAQ: ONCE)
In a report released yesterday, Reni Benjamin from Raymond James maintained a Buy rating on Spark Therapeutics (NASDAQ: ONCE). The company’s shares closed yesterday at $74.83.
Benjamin said:
“We are maintaining our Outperform rating for Spark. Hemophilia (WFH) 2018 World Congress, the company, along with its partner, Pfizer, provided an update on the ongoing Phase I/II study evaluating SPK-9001 for hemophilia B (Hem B). In addition, Spark’s competitor, BioMarin, provided an update on the ongoing Phase I/II trial of valoctocogene roxaparvovec (or BMN 270) in severe hemophilia A (Hem A).”
According to TipRanks.com, Benjamin is a 4-star analyst with an average return of 4.6% and a 46.1% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Invivo Therapeutics Holdings, Bellicum Pharmaceuticals, and Asterias Biotherapeutics.
Currently, the analyst consensus on Spark Therapeutics is Moderate Buy and the average price target is $83.70, representing an 11.9% upside.
In a report issued on May 8, William Blair also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
uniQure NV (NASDAQ: QURE)
In a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on uniQure NV (NASDAQ: QURE), with a price target of $50. The company’s shares closed yesterday at $32.34, close to its 52-week high of $33.33.
Amusa commented:
“We have previously noted Commissioner Gottlieb is relatively positive on the potential for GT to address many diseases. In remarks at the Medicine’s (ARM) annual board meeting, he stated “we’ve traditionally been willing to accept more uncertainty to facilitate timely access to promising therapies.” Given the severity of disease and lack of therapies (or high burden of treatment) for many indications targeted by GT, an accelerated approval process would be valuable, and the FDA intends to begin applying these new standards with hemophilia.”
According to TipRanks.com, Amusa is a 5-star analyst with an average return of 23.0% and a 52.0% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Nightstar Therapeutics Limited, and Arbutus Biopharma Corporation.
Currently, the analyst consensus on uniQure NV is Strong Buy and the average price target is $46.40, representing a 43.5% upside.
In a report issued on May 16, Wells Fargo also initiated coverage with a Buy rating on the stock with a $47 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
